Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol S Lim

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Development of an effective therapy for chronic myelogenous leukemiaDavid W Woessner, Carol S Lim, Michael W Deininger
Molecular Pharmaceutics|March 17, 2010
Effect of anabolic-androgenic steroids and glucocorticoids on the kinetics of hAR and hGR nucleocytoplasmic translocationAmy B Cadwallader, Douglas E Rollins, Carol S Lim
Molecular Pharmaceutics|February 14, 2013
A single mutant, A276S of p53, turns the switch to apoptosisShams Reaz, Mohanad Mossalam, Abood Okal, et al.
Therapeutic Delivery|November 16, 2013
Basics and recent advances in peptide and protein drug deliveryBenjamin J Bruno, Geoffrey D Miller, Carol S Lim
Biologics : Targets & Therapy|October 29, 2014
Resistant mutations in CML and Ph(+)ALL - role of ponatinibGeoffrey D Miller, Benjamin J Bruno, Carol S Lim
Journal of Ovarian Research|May 2, 2019
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancerKatherine Redd Bowman, Ji Hoon Kim, Carol S Lim
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 21, 2015
Delivery of drugs and macromolecules to the mitochondria for cancer therapyPhong Lu, Benjamin J Bruno, Malena Rabenau, et al.
Molecular Pharmaceutics|August 24, 2013
The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondriaKarina J Matissek, Mohanad Mossalam, Abood Okal, et al.
Pharmaceutical Research|March 18, 2014
Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or BaxKarina J Matissek, Abood Okal, Mohanad Mossalam, et al.
Biomolecules|January 21, 2023
The Challenges and Prospects of p53-Based Therapies in Ovarian CancerBryce Wallis, Katherine Redd Bowman, Phong Lu, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Development of an effective therapy for chronic myelogenous leukemiaDavid W Woessner, Carol S Lim, Michael W Deininger
Molecular Pharmaceutics|March 17, 2010
Effect of anabolic-androgenic steroids and glucocorticoids on the kinetics of hAR and hGR nucleocytoplasmic translocationAmy B Cadwallader, Douglas E Rollins, Carol S Lim
Molecular Pharmaceutics|February 14, 2013
A single mutant, A276S of p53, turns the switch to apoptosisShams Reaz, Mohanad Mossalam, Abood Okal, et al.
Therapeutic Delivery|November 16, 2013
Basics and recent advances in peptide and protein drug deliveryBenjamin J Bruno, Geoffrey D Miller, Carol S Lim
Biologics : Targets & Therapy|October 29, 2014
Resistant mutations in CML and Ph(+)ALL - role of ponatinibGeoffrey D Miller, Benjamin J Bruno, Carol S Lim
Journal of Ovarian Research|May 2, 2019
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancerKatherine Redd Bowman, Ji Hoon Kim, Carol S Lim
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 21, 2015
Delivery of drugs and macromolecules to the mitochondria for cancer therapyPhong Lu, Benjamin J Bruno, Malena Rabenau, et al.
Molecular Pharmaceutics|August 24, 2013
The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondriaKarina J Matissek, Mohanad Mossalam, Abood Okal, et al.
Pharmaceutical Research|March 18, 2014
Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or BaxKarina J Matissek, Abood Okal, Mohanad Mossalam, et al.
Biomolecules|January 21, 2023
The Challenges and Prospects of p53-Based Therapies in Ovarian CancerBryce Wallis, Katherine Redd Bowman, Phong Lu, et al.
Pageof 6